French tech star performer Nanobiotix secures funding to fight cancer

The year to date has been one of incredible progress for Euronext-listed Nanobiotix with the advances reflected in a share price that has appreciated 200 per cent in that short time. The group, whose technology promises a major advancement on traditional radiotherapy, revealed some fairly compelling data that points to the potential of its nano-medicine in cancer patients.

Daily Mail